• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Akero Therapeutics Inc.

    2/28/25 4:05:47 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email
    S-8 1 d830727ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    AKERO THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-5266573

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    601 Gateway Boulevard, Suite 350

    South San Francisco, CA

      94080
    (Address of Principal Executive Offices)   (Zip Code)

    Akero Therapeutics, Inc. 2019 Stock Option and Incentive Plan

    Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan

    (Full title of the plans)

    Andrew Cheng

    President and Chief Executive Officer

    601 Gateway Boulevard, Suite 350

    South San Francisco, CA 94080

    (Name and address of agent for service)

    (650) 487-6488

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    STATEMENT OF INCORPORATION BY REFERENCE

    This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 2,895,320 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2019 Stock Option and Incentive Plan and (ii) an additional 410,803 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2019 Employee Stock Purchase Plan, for which Registration Statements on Form S-8 relating to the same employee benefit plans are effective.

    Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed by the Registrant on June 20, 2019 (File No.  333-232234), March 16, 2020 (File No. 333-237220), March 18, 2021 (File No. 333-254454), March  2, 2022 (File No. 333-263194), March  17, 2023 (File No. 333-270662) and February  29, 2024 (File No. 333-277531) related to the Registrant’s 2019 Stock Option and Incentive Plan and 2019 Employee Stock Purchase Plan are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits

    Refer to the Exhibit Index on the next page for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.


    EXHIBIT INDEX

     

    Exhibit No.

      

    Description of Exhibit

     4.1    Fourth Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as amended (File No. 001-38944)) as filed with the SEC on June 24, 2019.
     4.2    Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as amended (File No. 001-38944)) as filed with the SEC on March 12, 2021.
     4.3    Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-38944) filed on June 12, 2024).
     4.4    Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A, as amended (File No. 333-231747) as filed with the SEC on June 10, 2019).
     5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
    23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    2019 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-231747)) as filed with the SEC on June 10, 2019.
    99.2    2019 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-231747)) as filed with the SEC on June 10, 2019.
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on this 28th day of February, 2025.

     

    AKERO THERAPEUTICS, INC.
    By:  

    /s/ Andrew Cheng

     

    Name: Andrew Cheng

    Title: President, Chief Executive Officer and Director

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Andrew Cheng and William White as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.


    Name

      

    Title

     

    Date

    /s/ Andrew Cheng

    Andrew Cheng, M.D., Ph.D.

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 28, 2025

    /s/ William White

    William White, J.D.

      

    Executive Vice President, Chief Financial Officer and Head of Corporate Development

    (Principal Financial Officer and Principal Accounting Officer)

      February 28, 2025

    /s/ Judy Chou

    Judy Chou, Ph.D.

       Director   February 28, 2025

    /s/ Seth L. Harrison

    Seth L. Harrison, M.D.

       Director   February 28, 2025

    /s/ Jane P. Henderson

    Jane P. Henderson

       Director   February 28, 2025

    /s/ Tom Heyman

    Tom Heyman

       Director   February 28, 2025

    /s/ Mark Iwicki

    Mark Iwicki

       Director   February 28, 2025

    /s/ Graham Walmsley

    Graham Walmsley, M.D., Ph.D.

       Director   February 28, 2025

    /s/ Yuan Xu

    Yuan Xu, Ph.D.

       Director   February 28, 2025
    Get the next $AKRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKRO

    DatePrice TargetRatingAnalyst
    9/4/2025$72.00Buy
    H.C. Wainwright
    8/4/2025$76.00Buy
    TD Cowen
    1/30/2025$35.00 → $63.00Neutral → Buy
    BofA Securities
    1/27/2025$50.00 → $72.00Buy
    H.C. Wainwright
    11/18/2024$65.00Buy
    Citigroup
    4/22/2024$30.00Neutral
    BofA Securities
    9/19/2023$69.00Overweight
    Cantor Fitzgerald
    8/28/2023$83.00Buy
    UBS
    More analyst ratings

    $AKRO
    SEC Filings

    View All

    SEC Form 15-12G filed by Akero Therapeutics Inc.

    15-12G - Akero Therapeutics, Inc. (0001744659) (Filer)

    12/19/25 4:05:42 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Akero Therapeutics Inc.

    25-NSE - Akero Therapeutics, Inc. (0001744659) (Subject)

    12/9/25 10:40:52 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Akero Therapeutics Inc.

    S-8 POS - Akero Therapeutics, Inc. (0001744659) (Filer)

    12/9/25 9:36:47 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    12/9/25 10:26:06 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    12/9/25 10:25:16 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    12/9/25 10:24:17 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novo Nordisk has completed its acquisition of Akero Therapeutics

    Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. ("Akero") (NASDAQ:AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right ("CVR"). Each CVR entitles its holder to an additional payment of 6 USD per share in cash (or aggregated value of 0.5 billion USD) upon US regulatory approval of Akero's lead candidate EFX for the tr

    12/9/25 8:51:19 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

    Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH Digital pathology reinforces fibrosis improvements observed through conventional pathology in the 96-week Phase 2b HARMONY trial SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxif

    11/7/25 7:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

    DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the appointments of Charles "Chip" R. Romp and Tom J. Heyman to its Board of Directors. These appointments further align SynOx's business with its forward strategy as the company nears topline data for emactuzumab and continues its focus on regulatory and commercial activities. In August 2025, SynOx completed enrollment in the Phase 3 TANGENT clinical trial; topline data are expected in the first quarter of 2026. Ray Barlow, Chief Execu

    10/21/25 7:00:00 AM ET
    $AKRO
    $EXEL
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $AKRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Akero Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akero Therapeutics with a rating of Buy and set a new price target of $72.00

    9/4/25 8:59:48 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Akero Therapeutics with a new price target

    TD Cowen initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $76.00

    8/4/25 8:20:06 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded Akero Therapeutics from Neutral to Buy and set a new price target of $63.00 from $35.00 previously

    1/30/25 7:09:02 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    Leadership Updates

    Live Leadership Updates

    View All

    Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

    -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second

    8/9/24 7:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

    SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late-stage clinical development of efruxifermin," remarked Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The entire leadership team looks forward to

    4/30/24 8:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. "Akero is thrilled to welcome Patrick to the team, especially following last year's HARMONY study results, which further demonstrate EFX's potential to treat NASH holistically and reverse fibrosis rapidly," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "Patrick's extensive experience in liver disease, and commercial stra

    1/10/23 8:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 3:59:41 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 1:22:38 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 6:51:23 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    3/27/25 7:42:13 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    2/7/25 7:54:28 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    12/11/23 9:06:30 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    Financials

    Live finance-specific insights

    View All

    Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

    Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious me

    1/27/25 6:30:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

    Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). Conferenc

    1/24/25 4:05:00 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

          50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies Investor webcast at 8:00 am ET Monday, March 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) --  Akero Therapeutics,

    3/4/24 6:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care